FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310778864> ?p ?o ?g. }

• W4310778864 endingPage "85" @default.
• W4310778864 startingPage "76" @default.
• W4310778864 abstract "Summary Given the promising activity and tolerability of FOLFIRINOX as a second-line treatment for advanced biliary tract cancer (BTC), it can be an attractive first-line treatment option as well. This is a single-arm, open-label, multicenter phase II study to evaluate the safety and efficacy of FOLFIRINOX as a first-line treatment for patients with advanced BTC. Primary endpoint was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), tumor response and safety. This study defined primary endpoint might be met when the lower limit value of 80% confidence interval [CI] of the median PFS ≥ 6.0 months. Between June 2016 and March 2020, 35 BTC patients (21 intrahepatic, 10 extrahepatic, 2 gallbladder, 2 ampulla) including 26 unresectable and 9 recurrent disease were enrolled. After a median follow-up of 13.9 months, the median PFS and OS were 7.4 (80% CI, 5.5–7.5) and 14.7 (80% CI, 11.8–15.7) months, respectively. Complete response was achieved in 1 (2.9%) and partial response in 10 (28.6%), giving an objective response rate of 31.4% and disease control rate of 74.3%. Major grade 3–4 adverse events included neutropenia (54.3%), leukopenia (34.4%), febrile neutropenia (17.1%), thrombocytopenia (8.6%), cholangitis (8.6%), anemia, nausea, diarrhea, and peripheral sensory neuropathy (2.9% each). FOLFIRINOX was well tolerable in patients with advanced BTC, however, this study did not meet the primary endpoint to conduct a phase III trial. Thus, further explorations are required to find a subset of patients and/or certain clinical scenario which might be beneficial from FOLFIRINOX." @default.
• W4310778864 created "2022-12-17" @default.
• W4310778864 creator A5015679349 @default.
• W4310778864 creator A5026988448 @default.
• W4310778864 creator A5030227876 @default.
• W4310778864 creator A5038774558 @default.
• W4310778864 creator A5043291695 @default.
• W4310778864 creator A5046522736 @default.
• W4310778864 creator A5050530209 @default.
• W4310778864 creator A5050881417 @default.
• W4310778864 creator A5060049548 @default.
• W4310778864 creator A5074130054 @default.
• W4310778864 creator A5078772421 @default.
• W4310778864 creator A5080299485 @default.
• W4310778864 date "2022-12-02" @default.
• W4310778864 modified "2023-10-14" @default.
• W4310778864 title "A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer" @default.
• W4310778864 cites W1903979702 @default.
• W4310778864 cites W2019607817 @default.
• W4310778864 cites W2034770797 @default.
• W4310778864 cites W2054178056 @default.
• W4310778864 cites W2071125719 @default.
• W4310778864 cites W2087336559 @default.
• W4310778864 cites W2108756633 @default.
• W4310778864 cites W2115261608 @default.
• W4310778864 cites W2144412903 @default.
• W4310778864 cites W2151253787 @default.
• W4310778864 cites W2159243852 @default.
• W4310778864 cites W2168106806 @default.
• W4310778864 cites W2227346470 @default.
• W4310778864 cites W2481516632 @default.
• W4310778864 cites W2581340408 @default.
• W4310778864 cites W2745824859 @default.
• W4310778864 cites W2769183729 @default.
• W4310778864 cites W2888369063 @default.
• W4310778864 cites W2897311709 @default.
• W4310778864 cites W2946053006 @default.
• W4310778864 cites W2977982707 @default.
• W4310778864 cites W2996284088 @default.
• W4310778864 cites W3000398147 @default.
• W4310778864 cites W3010944770 @default.
• W4310778864 cites W3021696184 @default.
• W4310778864 cites W3024247862 @default.
• W4310778864 cites W3032507003 @default.
• W4310778864 cites W3046384500 @default.
• W4310778864 cites W3118440195 @default.
• W4310778864 cites W3144916167 @default.
• W4310778864 cites W3160562559 @default.
• W4310778864 cites W3165871895 @default.
• W4310778864 cites W3178451450 @default.
• W4310778864 cites W3205618463 @default.
• W4310778864 cites W3206691421 @default.
• W4310778864 cites W3213003275 @default.
• W4310778864 cites W4281630496 @default.
• W4310778864 doi "https://doi.org/10.1007/s10637-022-01322-7" @default.
• W4310778864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36459291" @default.
• W4310778864 hasPublicationYear "2022" @default.
• W4310778864 type Work @default.
• W4310778864 citedByCount "0" @default.
• W4310778864 crossrefType "journal-article" @default.
• W4310778864 hasAuthorship W4310778864A5015679349 @default.
• W4310778864 hasAuthorship W4310778864A5026988448 @default.
• W4310778864 hasAuthorship W4310778864A5030227876 @default.
• W4310778864 hasAuthorship W4310778864A5038774558 @default.
• W4310778864 hasAuthorship W4310778864A5043291695 @default.
• W4310778864 hasAuthorship W4310778864A5046522736 @default.
• W4310778864 hasAuthorship W4310778864A5050530209 @default.
• W4310778864 hasAuthorship W4310778864A5050881417 @default.
• W4310778864 hasAuthorship W4310778864A5060049548 @default.
• W4310778864 hasAuthorship W4310778864A5074130054 @default.
• W4310778864 hasAuthorship W4310778864A5078772421 @default.
• W4310778864 hasAuthorship W4310778864A5080299485 @default.
• W4310778864 hasBestOaLocation W43107788641 @default.
• W4310778864 hasConcept C121608353 @default.
• W4310778864 hasConcept C126322002 @default.
• W4310778864 hasConcept C141071460 @default.
• W4310778864 hasConcept C197934379 @default.
• W4310778864 hasConcept C203092338 @default.
• W4310778864 hasConcept C2776694085 @default.
• W4310778864 hasConcept C2777063308 @default.
• W4310778864 hasConcept C2777148230 @default.
• W4310778864 hasConcept C2778375690 @default.
• W4310778864 hasConcept C2778850193 @default.
• W4310778864 hasConcept C2780580376 @default.
• W4310778864 hasConcept C2780873365 @default.
• W4310778864 hasConcept C2780962732 @default.
• W4310778864 hasConcept C31760486 @default.
• W4310778864 hasConcept C526805850 @default.
• W4310778864 hasConcept C535046627 @default.
• W4310778864 hasConcept C71924100 @default.
• W4310778864 hasConcept C90924648 @default.
• W4310778864 hasConceptScore W4310778864C121608353 @default.
• W4310778864 hasConceptScore W4310778864C126322002 @default.
• W4310778864 hasConceptScore W4310778864C141071460 @default.
• W4310778864 hasConceptScore W4310778864C197934379 @default.
• W4310778864 hasConceptScore W4310778864C203092338 @default.
• W4310778864 hasConceptScore W4310778864C2776694085 @default.
• W4310778864 hasConceptScore W4310778864C2777063308 @default.

• next